Sayre Therapeutics will be able to distribute, market and sell LUTRATE Depot in one and three month formulations for India, Sri Lanka, Bangladesh and Nepal
Sayre Therapeutics, a commercial healthcare company with a portfolio of oncology and immunology focussed commercial products, has entered into an exclusive license agreement with GP Pharm. This will enable them to distribute, market and sell Lutrate Depot formulation in one and three month formulations in India, Sri Lanka, Bangladesh and Nepal. GP Pharm will supply Lutrate to Sayre on an exclusive basis from its manufacturing facility in Barcelona, Spain.
Vandana Subramanian, Senior VP, BD & Corporate Strategy said “Our collaboration with GP Pharm helps us bring an EMA approved best-in-class differentiated Leuprolide Acetate Depot formulation to South Asia. This medicine provides a further fillip to our efforts to build a portfolio for oncology diseases with advanced options for patients suffering from prostate cancer. Lutrate will greatly benefit the South Asian patient community and improve their quality of life.”
“We are pleased that we have been able to expand the availability of Lutrate to the South-Asian region with our committed and capable partner, Sayre Therapeutics,” said Dr Antonio Parente, GP Pharm’s Executive President. “This collaboration represents one step further in our worldwide expansion and it will allow us to position Lutrate in new territories and continue with the corporate vision of GP Pharm: bringing science to the society by developing innovative products.”